A Study in Patients With Neovascular Age Related Macular Degeneration or Macular Edema Secondary To Retinal Vein Occlusion to Evaluate Usability of the Ranibizumab (Lucentis®) Prefilled Syringe (PFS)

Inclusion Criteria: Ocular * Study eye deemed to be indicated for ranibizumab ITV therapy at the discretion of the retina specialist Exclusion Criteria: Concurrent Ocular Conditions * Patients legally blind in one or both eyes * History of or any current clinically relevant intraocular inflammation or ocular inflammatory reaction (any grading from trace and greater is excluded), including non-infectious uveitis or uveitis, or sterile inflammatory reaction after the past ITV injections with any agent * Active disorder of ocular adnexa and skin in the study eye, including ocular surface infections * History of or any current indication of excessive bleeding and recurrent hemorrhages, including any prior excessive intraocular (including subconjunctival) bleeding or hemorrhages after ITV injection or intraocular procedures * Uncontrolled intraocular pressure greater than (\>) 25 millimeters of mercury (mmHg) in the study eye (uncontrolled means that it occurs even with intraocular pressure-lowering therapy) * Use of therapies that are known to be toxic to any ocular tissues within the 6 months prior to enrollment Prior Ocular Therapies * Treatment with any ITV injection within the 27 days prior to Day 1 * Any invasive intraocular surgery, prior long-acting therapeutic agent, or ocular drug release device implantation (approved or investigational) in the study eye at any time during the past 3 months General * Receipt of any systemic (non-ocular) investigational drug with…